LYEL - Lyell Immunopharma, Inc.

21.49
-1.130   -5.258%

Share volume: 63,263
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$22.62
-1.13
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 23%
Liquidity 58%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.11%
1 Month
11.40%
3 Months
-13.38%
6 Months
29.54%
1 Year
4,873.39%
2 Year
855.11%
Key data
Stock price
$21.49
P/E Ratio 
N/A
DAY RANGE
$21.17 - $23.68
EPS 
-$11.26
52 WEEK RANGE
$0.39 - $45.00
52 WEEK CHANGE
$4,422.31
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
23.307 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-05-2025
BETA 
1.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$76,982
AVERAGE 30 VOLUME 
$90,228
Company detail
CEO: Elizabeth Homans
Region: US
Website: lyell.com
Employees: 270
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Lyell Immunopharma, Inc. engages in developing T cell therapies for patients with solid tumors. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers. The company entered into research and development collaboration with GlaxoSmithKline for NY-ESO-1 program.

Recent news